Literature DB >> 28111792

Inhibition of Propionibacterium acnes lipase activity by the antifungal agent ketoconazole.

Mizuki Unno1, Otomi Cho1, Takashi Sugita1.   

Abstract

The common skin disease acne vulgaris is caused by Propionibacterium acnes. A lipase secreted by this microorganism metabolizes sebum and the resulting metabolites evoke inflammation in human skin. The antifungal drug ketoconazole inhibits P. acnes lipase activity. We previously showed that the drug also inhibits the growth of P. acnes. Thus, ketoconazole may serve as an alternative treatment for acne vulgaris, which is important because the number of antibiotic-resistant P. acnes strains has been increasing.
© 2017 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Propionibacterium acnes; ketoconazole; lipase

Mesh:

Substances:

Year:  2017        PMID: 28111792     DOI: 10.1111/1348-0421.12464

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

1.  The impact of skin care products on skin chemistry and microbiome dynamics.

Authors:  Amina Bouslimani; Ricardo da Silva; Tomasz Kosciolek; Stefan Janssen; Chris Callewaert; Amnon Amir; Kathleen Dorrestein; Alexey V Melnik; Livia S Zaramela; Ji-Nu Kim; Gregory Humphrey; Tara Schwartz; Karenina Sanders; Caitriona Brennan; Tal Luzzatto-Knaan; Gail Ackermann; Daniel McDonald; Karsten Zengler; Rob Knight; Pieter C Dorrestein
Journal:  BMC Biol       Date:  2019-06-12       Impact factor: 7.431

2.  Two Percentage of Ketoconazole Cream for the Treatment of Adult Female Acne: A Placebo-Controlled Trial.

Authors:  Ahsan Anwar; Syed Kamran Ul Hassan
Journal:  Cureus       Date:  2020-11-19

3.  Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli.

Authors:  Sarah Lebeer; Eline F M Oerlemans; Ingmar Claes; Tim Henkens; Lize Delanghe; Sander Wuyts; Irina Spacova; Marianne F L van den Broek; Ines Tuyaerts; Stijn Wittouck; Ilke De Boeck; Camille N Allonsius; Filip Kiekens; Julien Lambert
Journal:  Cell Rep Med       Date:  2022-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.